DV
Dividend Vision

RIGL — Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc (RIGL)

Total return is -93.3% over the past 25.7 years, 915.0 points behind SPY at 821.7%. Its deepest 1-year drawdown was 50.1%.

This appears to be a single-stock holding rather than a diversified ETF, consisting of Rigel Pharmaceuticals Inc equity. As a concentrated position in a biopharmaceutical company, it does not currently offer dividend distributions and carries expense ratio and asset information that is not publicly available through standard ETF data sources. This holding structure appeals primarily to investors seeking direct exposure to a specific pharmaceutical company's equity performance rather than those pursuing dividend income or diversified ETF-based strategies.

RIGL key facts

Asset type
Stock
Asset class
Equity
Inception date
11/29/2000
Last close
$42.58
Market cap
$733,977,472
Average volume
224043.0
Beta
1.133
Payout ratio
0.0
P/E ratio
2.0565
Forward P/E
9.009
EPS
$19.29